Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage?: A multicenter experience

Radioiodine-refractory thyroid cancers (IRTCs) are uncommon and have a poor prognosis. Treatment options for radioiodine-refractory and anaplastic tumors (ATCs) are limited. Although the genomic landscape of thyroid cancer has been studied, there is little evidence on whether next-generation sequenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Moore, Assaf, Bar, Yael, Maurice-Dror, Corinne, Finkel, Inbar, Goldvaser, Hadar, Dudnik, Elizabeth, Goldstein, Daniel A., Gordon, Noa, Billan, Salem, Gutfeld, Orit, Wolf, Ido, Popovtzer, Aron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238320/
https://www.ncbi.nlm.nih.gov/pubmed/34160418
http://dx.doi.org/10.1097/MD.0000000000026388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238320/
https://www.ncbi.nlm.nih.gov/pubmed/34160418
http://dx.doi.org/10.1097/MD.0000000000026388

Ejemplares similares